SCHEMBL375579

SCHEMBL375579

CNC(=O)c1ccccc1N

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.59
HSD17B10 Q99714 4/20 0.59
GAA P10253 2/20 0.59
CFTR P13569 1/20 0.59
KDM4E B2RXH2 8/20 0.57
HPGD P15428 6/20 0.57
MAPT P10636 1/20 0.55
PLK1 P53350 1/20 0.55
RCE1 Q9Y256 1/20 0.53
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
FADS1 O60427 2/20 0.51
CASP3 P42574 1/20 0.51
SENP8 Q96LD8 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
SENP6 Q9GZR1 1/20 0.51
USP2 O75604 1/20 0.49
PTGS1 P23219 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27744263 0.98 ALDH1A1 (0.57) ALDH1A1HSD17B10GAACFTRKDM4E
Acetic Acid SCHEMBL28650473 0.94 KDM4E (0.56) ALDH1A1HSD17B10GAACFTRKDM4E
SCHEMBL14227351 0.86 PLK1 (0.55) ALDH1A1HSD17B10GAACFTRKDM4E
SCHEMBL31260535 0.86 ALDH1A1 (0.53) ALDH1A1HSD17B10GAACFTRKDM4E
SCHEMBL2344909 0.84 GAA (0.71) ALDH1A1GAAPLK1
SCHEMBL5252014 0.83 PLK1 (0.52) ALDH1A1HSD17B10GAACFTRKDM4E
SCHEMBL9254644 0.83 ALDH1A1 (0.55) ALDH1A1HSD17B10GAACFTRKDM4E
SCHEMBL7653624 0.82 KDM4E (0.47) ALDH1A1HSD17B10GAACFTRKDM4E
SCHEMBL9921278 0.82 KDM4E (0.60) ALDH1A1HSD17B10GAACFTRKDM4E
SCHEMBL2299529 0.82 PLK1 (0.50) ALDH1A1HSD17B10GAACFTRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 593 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4646271-A1 SUBSTITUTED SPIROCYCLIC-PYRROLOQUINAZOLINONES AND SPIROCYCLIC-PIPERIDINOQUINAZOLINONES Mirati Therapeutics, Inc. (US) 2025-11-12 EP claimed
CN-120079371-A Oxygen vacancy-containing tungsten trioxide catalyst and preparation method and application thereof 南京理工大学 2025-06-03 CN claimed
CN-118878468-A Diamino pyrimidine compound containing phenyl nitrogen mustard fragment and preparation method and application thereof 贵州大学 2024-11-01 CN claimed
WO-2024148150-A1 SUBSTITUTED SPIROCYCLIC-PYRROLOQUINAZOLINONES AND SPIROCYCLIC-PIPERIDINOQUINAZOLINONES Mirati Therapeutics, Inc. (US) 2024-07-11 WO claimed
WO-2023127883-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL 日本新薬株式会社 2023-07-06 WO claimed
CN-112142620-B Synthetic method of 2-amino-3, 5-dichloro-N-methylbenzamide 江西省科学院应用化学研究所 2023-03-31 CN claimed
CN-112142620-A Synthetic method of 2-amino-3, 5-dichloro-N-methylbenzamide 江西省科学院应用化学研究所 2020-12-29 CN claimed
CN-111454219-A 5-trifluoromethyl pyrimidine derivative and preparation method and application thereof 贵州大学 2020-07-28 CN claimed
CN-104744379-B A kind of quianzolinones and its synthetic method 三峡大学 2017-10-27 CN claimed
EP-2580207-B1 NITROGEN CONTAINING HETEROARYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2017-09-27 EP claimed
CN-104557738-A Green synthesis method of 4(3H)-quinazolinone UNIV HUNAN 2015-04-29 CN claimed
CN-104447580-A Method for synthesizing quinazolone compounds UNIV HUNAN 2015-03-25 CN claimed
US-8703768-B2 Nitrogen containing heteroaryl compounds HOFFMANN-LA ROCHE INC. (US) 2014-04-22 US claimed
US-8623866-B2 2014-01-07 US claimed
CN-103432077-A Chidamide solid dispersion preparation BEIJING GANHANG MEDICINE SCIENCE & TECHNOLOGY CO LTD 2013-12-11 CN claimed
EP-2580207-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2013-04-17 EP claimed
WO-2012014127-A1 5-LIPOXYGENASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2012-02-02 WO claimed
WO-2011154327-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 WO claimed
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 US claimed
EP-1114047-B1 AN IMPROVED PROCESS FOR THE PREPARATION OF THIAZOLIDINE-2,4-DIONE DERIVATIVES REDDYS LAB LTD DR (IN) 2003-03-19 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS PDE10A, PDE3A, PDE2A ALDH1A1 271/4885HSD17B10 88/4885GAA 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.